Salivary gland cancers represent a rare group of tumors composed by over 20 histological subtypes. Initially treated as one single disease, its diagnosis, prognosis, and treatment are currently being stratified based on morphology. More recently, insight has been provided on the molecular characterization of each subtype, further improving diagnostic accuracy and paving the way for personalized therapy. In this article, we provide a comprehensive review of recent breakthroughs, preliminary results of novel therapy, and future directions on the treatment of these complex malignancies.
of the WHO Classification incorporated the most frequently observed molecular characteristics of SGCs ( Figure 2 ).
The purpose of this article is to review the molecular characteristics of different histotypes of SGC and promising pathways currently being studied and experimented on for recurrent or metastatic disease, as the main curative approach to localized disease is still surgery, with or without postoperative radiotherapy. For ease of discussion regarding therapeutics, we will divide the article into two main subgroups: ACC and non-ACC, as many clinical studies utilize this subdivision. We will then discuss the most common and/or therapeutically relevant histological subtypes within the non-ACC group.
| Adenoid cystic carcinoma
ACC accounts for over half the cases of metastatic SGC. 10 While the majority of patients will not require immediate treatment, given the overall indolent presentation of this SGC subtype, chemotherapy is still the most popular treatment choice when therapy is required, although there is no clear standard of care. 6 Nonetheless, they represent a heterogeneous group and are often refractory to chemotherapy.
| Chemotherapy
There are no randomized trials in this setting, and the results obtained with chemotherapy for ACC are overall unsatisfactory. 10 The most studied regimen cyclophosphamide, doxorubicin, and cisplatin (CAP) provided an overall response rate (ORR) of 27%, with significant toxicity. 11 Another chemotherapy regimen with some activity in ACC is the combination of cisplatin and vinorelbine, which rendered objective responses in 21% of patients when administered in first or second line. The low burden of mutation load in ACC results in few potential targets. 13, 14 A translocation (t) of chromosome 6q
of v-myb avian myeloblastosis viral oncogene homolog (MYB) with chromosome 9p of the nuclear factor I/B (NFIB) gene results in the fused oncogene MYB-NFIB, one of the most common genetic abnormalities, present in 60%-80% of ACC. [13] [14] [15] [16] [17] [18] Subsequently, novel MYBL1-NFIB and MYBL1-RAD51B gene fusions resulting from t(8, 9) and t (8, 14) , respectively, along multiple other rearrangements in the MYBL1 gene were identified in 35% of the t(6, 9) negative tumors. 19, 20 As a result, downstream deregulation of critical cellular mechanisms involved in apoptosis, cell adhesion, and cell cycle regulation occurs. 15 Additionally, as commonly observed in several other human cancers, MYB is overexpressed in the surface of the cell in the majority of ACC, often not correlating with the presence of a concurrent translocation, indicating that other mechanisms may be involved in triggering its expression. 16, 18 Conflicting results, however, were found regarding the effect of MYB-NFIB translocation on long-term outcomes, 16, 20, 21 and its role as a potential target is yet to be determined. This genetic abnormality is particularly difficult to target clinically, as MYB is a transcription factor.
NOTCH1
Recent findings demonstrate that a subset of patients harboring NOTCH1 mutations has significantly higher Notch1 pathway activation as compared to wild-type, conferring an aggressive pattern to these tumors in 11%-29% of cases. 13, 14, 22 Patients with NOTCH1 mutations are significantly more likely to present with advanced disease stage at diagnosis, develop liver and bone metastasis, and have worse prognosis than their wild-type counterparts. 23 The
Notch developmental pathway is involved in relevant cancer-related functions, including maintenance of stem cells, cell fate specification, proliferation, and angiogenesis. 24 Although it can be deregulated in several cancers, its role in cancer evolution and therapeutics is not fully understood. A NOTCH1-mutated patient with ACC-derived xenograft model showed susceptibility to a Notch1 inhibitor and an index patient with ACC with NOTCH1 mutation had an objective response to a specific monoclonal antibody targeting Notch1 as part of a phase I clinical trial. 23 Preliminary results of a phase I clinical trial with the pan-Notch inhibitor LY3039478 showed objective response in 1 out of 22 unselected patients. However, the disease control rate (DCR) was 73%, with four patients with stable disease for over 6 months. 25 These provoking results warrant additional investigation, ideally in biomarker-selected patients, currently underway through ongoing clinical trials (NCT02069730). The Notch pathway, along with SRYrelated HMG-box 10 (SOX10), and their effector fatty acid binding protein 7 (FABP7), may be closely related to the recently suggested role of cancer stem cells in ACC. 26, 27 An ongoing phase 1b/2 study with amcasertib, a first-in-class cancer stemness kinase inhibitor, was well tolerated and showed activity in 14 patients with ACC, with no responses but a DCR of 86%, with 50% of the patients experiencing disease stabilization for more than 6 months (disease progression within 6 months was a study entry criteria).
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PI3K/AKT/mTOR
Mutations in genes important to the FGF/IGF/PI3K pathway were identified in 30% of ACC. 29 A retrospective study found that high expression of phosphorylated AKT/mTOR is associated with a less aggressive phenotype, even resulting in significantly improved overall survival. 30 Everolimus was tested for ACC in a phase II trial, with 79% of patients achieving stable disease. 31 Despite no patients achieving a partial response (PR) by RECIST, 44% of 18 patients with pretreatment and post-treatment positron emission tomography-CT scans available had a metabolic PR. Median progression-free survival (PFS) was numerically longer for patients with metabolic PR than those with metabolic stable disease (SD) or progressive disease (PD).
Histone deacetylase inhibitors
Epigenetics represents a crucial player for tumor development. It has been observed that malignant SGC's chromatin were hypoacetylated compared to benign tumors. 32 Moreover, acetyl-H3 expression was inversely correlated with Ki67, providing insight that histone modification and epigenetic mechanisms may play a role in the behavior of SGC.
In patient-derived xenografts and ACC primary cells, cisplatin reduced tumor viability but enriched the population of cancer stem cells. 33 Administration of vorinostat, a histone deacetylase (HDAC) inhibitor, reduced the number of detectable cancer stem cells in vivo and in vitro. Furthermore, the combination of both vorinostat and cisplatin was extremely effective in depleting cancer stem cells and reduce tumor viability. Vorinostat was then tested in 30 patients with ACC in a phase II study, demonstrating a 90% rate of SD (27/30), with 7% of the patients (2/30) achieving a PR. 34 There is an ongoing phase I/II trial combining vorinostat and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma or salivary gland cancer (NCT02538510).
| Immunotherapy
Sridharan et al 35 found no patients with ACC having significant PD-L1 expression, but PD-L2 is expressed in over 60% of the primary tumors and 73% of the metastatic sites. They have also reported that chemoradiation increases CD8+ effector T cells (expressing LAG-3, TIM-3, or PD-1) in the peripheral blood. Pembrolizumab was tested for SGCs in Keynote-028, but it showed no responses in ACC subtype. 36 An ongoing phase II trial is comparing pembrolizumab with or without radiation for recurrent or metastatic ACC (NCT03087019). 
| Other pathways
Vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor 1 (FGFR1) are commonly overexpressed in ACC and represents potential therapeutic targets. Several inhibitors of these pathways, including sorafenib, sunitinib, regorafenib, dovitinib, nintedanib, axitinib, and pazopanib have been studied in ACC and showed some clinical benefit, with ORR in the range of 6% to 10%, and prolonged SD (>6 months) in up to 85% of unselected patients (Table 2) . 13, [37] [38] [39] [40] [41] [42] [46] [47] [48] [49] One of the caveats of these trials is that in not all of them disease progression within a prespecified time frame was an inclusion criteria, making it difficult to interpret the value of prolonged disease stabilization in the context of an overall indolent disease. More recently, the new-generation multikinase inhibitor lenvatinib that is active against VEGFR2, FGFR1-3, KIT, RET, and platelet-derived growth factor receptor (PDGFR) α and β demonstrated an ORR of 12%-16% in two phase 2 studies, with 25% to 27% of patients with ACC achieving at least a 20% reduction in size of targeted tumor lesions. While these Abbreviations: DCR, disease control rate; mPFS, median progression-free survival; N, number; NS, not specified; ORR, overall response rate.
results are encouraging, toxicity was common and dose reduction occurred in 72% to 86% of patients; however, it did not seem to impact quality of life which was a secondary endpoint in one of the studies. 44, 45 Targeting overexpression of HER2 and C-KIT with agents such as trastuzumab, lapatinib, imatinib, and dasatinib failed to show activity in ACC, likely as a result of the lack of an underlying gene amplification and/or driver mutation. 43 Recently, a comprehensive genomic profiling was performed in 48 MEC. 58 A total of 183 genomic abnormalities were found, occurring more frequently in high-grade tumors compared to low grade. In high-grade MEC, the most frequently observed mutations were on TP53, PI3K/mTOR pathway, and CDKN2A (56%, 52%, and 36%, respectively). ERBB2, a known potential target with anti-HER2 agents, was amplified in 8.3% of cases. Other targetable mutations included BRCA (10.5%), FGFR (12.5%), and one BRAF V600E mutation. Moreover, CRTC1/MAML2 translocations were found in 50%-65% in different studies. [59] [60] [61] Despite having its oncogenic functions described, it was not correlated with worse outcomes.
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| Salivary duct carcinoma
SDC is an aggressive subtype of SGC, frequently presenting with locoregional and distant dissemination. Similarly to the other subtypes, current treatment options rely on platinumbased regimens, usually with taxanes, rendering responses in 39% of patients, usually of short duration. 63 In contrast, HER2 seems to be overexpressed in the surface of the majority of patients and amplified in about 30%. [64] [65] [66] SDC is morphologically similar to invasive ductal carcinoma of the breast and also share several IHC charactheristics. 67 Case series in the literature demonstrated activity of trastuzumab as single agent or in combination with cytotoxic chemotherapy in SDC. [68] [69] [70] [71] [72] [73] [74] A series of 13 patients with HER2 expression 1-3+ treated with carboplatin, paclitaxel, and trastuzumab in the adjuvant or metastatic setting showed response in all metastatic patients, and 62% of the adjuvant group had no evidence of disease at 2 years of follow-up. 69 MyPathway, a phase 2, multibasket study evaluating the efficacy of targeted treatments in nonindicated tumor types with different molecular alterations, included seven patients with salivary gland cancer and HER2 overexpression, amplification, or activating mutations (Table 3) . Treatment with standard doses of trastuzumab and pertuzumab in those patients showed an ORR of 80% (five of six patients). 75 Lastly, Takahashi et al 76 demonstrated an ORR of 76% and a median PFS of 9.8 months with the combination of trastuzumab and docetaxel in a phase 2 trial that treated 48 patients. In addition, BRAF mutations were found in about 5% of SDC. 79 A single patient with SDC included in a trial testing vemurafenib for nonmelanoma BRAF V600E-mutated patients demonstrated a near-complete response to therapy. 80 Other potential targetable genomic abnormalities were found in SDC, such as PI3K/AKT/mTOR pathway mutations (53.6%), RAS (26.8%), and NOTCH1 (17.1%), among others. 79 Androgen receptor is overexpressed in 43%-99% of SDC. 79, 81, 82 Interestingly, its expression was neither significantly found in benign salivary gland tumors nor in the other malignant histologic subtypes, suggesting a role in its histogenesis and possibly in the clinical management of the disease. 83 Indeed, responses to androgen deprivation therapy (ADT) approaches with bicalutamide and/or luteinizing hormone releasing hormone (LHRH) analogues reported in the literature vary from 13% to 65% in small case series. 81, 84, 85 Recently, a phase II study of combined ADT with LHRH agonist and bicalutamide yielded an ORR of 42% in 36 eligible patients (34 with SDC). 77 The median PFS was 8.8 months and the median OS was 30.5 months. Other prospective trials are ongoing to evaluate ADT alone and in comparison to chemotherapy for both chemotherapy-naïve and refractory patients (NCT02749903l; NCT02867852; NCT01969578).
| Secretory carcinoma
Secretory carcinoma (SC), previously referred as mammary analog SC, was first described in 2010 as a tumor that bears a morphologic similarity with SC of the breast. It has a distinct histologic pattern among SGC and is molecularly characterized by a balanced chromosomal translocation t(12;15) (p13;q25), resulting in an ETV6-NTRK3 fusion, identical to that in SC of the breast. 86 SC is regarded as a low-grade carcinoma, and its prognosis seems to be overall favorable, although a high-grade transformation can occur in a subset of patients. 86 Clinically, TRK fusion is being targeted in early phase trials with great promise. Larotrectinib (LOXO-101) was the first selective TRK inhibitor to be tested. Results of a phase II study demonstrated that 10 out of 12 patients with SC achieved an objective response. Among the 55 overall patients whose varied tumor types harbored a TRK fusion, ORR was 75% by an independent radiology review committee and 80% by investigator's assessment, with 71% of responses ongoing at 1 year. 78 In a phase I study of the pan-TKR inhibitor entrectinib, the solely enrolled patient with SC harboring ETV6-NTRK3 translocation achieved a 90% tumor burden reduction. 93 A phase II study is currently ongoing (NCT02568267). As some SC can be misclassified as acinic cell carcinoma, and given encouraging clinical activity of the pan-NTRK inhibitors, we encourage clinicians to test both histologies for NTRK fusions. An IHC test is being developed for use as a surrogate marker for the presence of NTRK fusions.
| Adenocarcinoma, NOS
Adenocarcinoma, NOS is usually a moderate to high-grade tumor that often recurs locally and metastasize. Chemotherapy has some activity either in monotherapy or in combination regimens. While single-agent paclitaxel resulted in 29% ORR, 8 platinum doublet with gemcitabine or vinorelbine led to an ORR of 38% and 47%, respectively. 12, 56 Similarly to the other subtypes, targeted therapy with sorafenib, pazopanib, and nintedanib yielded disappointing response rates, although over half of the patients had stable disease. 40 ,42,47
| Immunotherapy in non-ACC SGC
Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 and the PD-1/PD-L1 has demonstrated promise in a variety of malignancies. 94 In a retrospective study including 219 patients with SGC (76% non-ACC), PD-L1 expression >1% was associated with significantly poorer PFS (5-year PFS of 20% for PD-L1 positive tumors and 55% for PD-L1 negative) and OS (41% and 81%, respectively). 95 Results of the phase 1b Keynote-028 study showed an ORR of 12% in the cohort of SGC, with median PFS of 3.8 months (95% CI: 1.9-5.5 months) and median OS of 13.2 months (95% CI: 5.2 months-not reported). 36 Responses were seen in adenocarcinoma (n = 2) and highgrade serous carcinoma (n = 1). The efficacy of pembrolizumab in SGC is being further investigated both as single agent (NCT02628067) and in combination with vorinostat (NCT02538510). Additionally, nivolumab is also being evaluated as single agent (NCT03132038) and in combination with ipilimumab (NCT02834013) in ongoing phase 2 studies.
| CONCLUSION
In conclusion, the field of SGC, which has been without major breakthroughs in the past decades, is undergoing significant scientific discoveries in the molecular level. Several targets are already under clinical investigation and many more are still to be tested. With the advance of targeted therapy against driver mutations and improvements in immunooncology, the future hold promise to this rare, yet highly incurable disease.
